Biocon said on Monday that its Board of Directors has authorized the appointment of Peter Bains as Group CEO, effective today.
He would report directly to Kiran Mazumdar-Shaw, the chairperson of Biocon Group.
Bains has resigned from his position as an independent director on the Biocon Board with immediate effect to take on this strategic managerial responsibility.
Peter has a unique fit and profile for the role, according to Mazumdar-Shaw, with extensive global leadership experience and success in the biopharmaceutical field, as well as a comprehensive understanding of the Biocon Group, having led Syngene for 5 years, leading it through its very successful IPO in 2015.
Siddharth Mittal, CEO & MD Biocon Limited, Shreehas Tambe, CEO & MD Biocon Biologics Limited, and Jonathan Hunt, CEO & MD Syngene International Limited will continue to run their businesses independently and will collaborate with Peter to strengthen synergistic strategic leadership at the Group level in order to maximize the combined value of all three companies, said Mazumdar-Shaw.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.